Vertex Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
— Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — — Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to-severe acute pain and on track to complete this quarter — — Entered into agreement to acquire Alpine Immune Sciences, including povetacicept, a Phase 3-ready asset in IgA nephropathy and potential pipeline-in-a-product — BOSTON, May 06, 2024 BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. "Vertex delivered a strong start to 2024 with 13 percent product revenue growth and outstanding execution across the business. This quarter, we continued to expand our leadership in CF including completion of the regulatory submissions for the vanzacaftor triple, advanced the global launch of CASGEVY ™ , and initiated the rolling submission for suzetrigine in moderate-to
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. [Yahoo! Finance]Yahoo! Finance
- Jennifer Schneider Elected to Vertex Board of Directors [Yahoo! Finance]Yahoo! Finance
- Jennifer Schneider Elected to Vertex Board of DirectorsBusiness Wire
- Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised [Yahoo! Finance]Yahoo! Finance
- Vertex Is Writing A New Playbook For Pharma R&D. And It's Working. [Forbes]Forbes
VRTX
Earnings
- 5/6/24 - Beat
VRTX
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- VRTX's page on the SEC website